Cantargia Valuation
Is CANTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CANTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CANTA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CANTA's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CANTA?
Other financial metrics that can be useful for relative valuation.
| What is CANTA's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | SEK 862.23m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -2.9x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does CANTA's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 22.9x | ||
HAMLET B Hamlet BioPharma | 9.6x | n/a | SEK 731.4m |
CRNO B Cereno Scientific | 6.1x | 12.9% | SEK 1.2b |
FLUO FluoGuide | 61.3x | 40.9% | SEK 544.5m |
INIT Initiator Pharma | 14.6x | -5.5% | SEK 523.9m |
CANTA Cantargia | 6.5x | 30.6% | SEK 862.2m |
Price-To-Book vs Peers: CANTA is good value based on its Price-To-Book Ratio (6.5x) compared to the peer average (22.9x).
Price to Earnings Ratio vs Industry
How does CANTA's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Book vs Industry: CANTA is expensive based on its Price-To-Book Ratio (6.5x) compared to the Swedish Biotechs industry average (2.2x).
Price to Book Ratio vs Fair Ratio
What is CANTA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 6.5x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate CANTA's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | SEK 4.69 | SEK 12.67 +169.8% | 16.2% | SEK 15.00 | SEK 10.00 | n/a | 3 |
| Jun ’25 | SEK 4.80 | SEK 12.67 +163.9% | 16.2% | SEK 15.00 | SEK 10.00 | n/a | 3 |
| May ’25 | SEK 3.34 | SEK 12.67 +279.7% | 16.2% | SEK 15.00 | SEK 10.00 | n/a | 3 |
| Apr ’25 | SEK 3.49 | SEK 12.67 +262.9% | 16.2% | SEK 15.00 | SEK 10.00 | n/a | 3 |
| Mar ’25 | SEK 2.72 | SEK 12.67 +365.7% | 16.2% | SEK 15.00 | SEK 10.00 | n/a | 3 |
| Feb ’25 | SEK 3.47 | SEK 13.67 +294.1% | 24.1% | SEK 18.00 | SEK 10.00 | n/a | 3 |
| Jan ’25 | SEK 3.74 | SEK 13.67 +265.6% | 24.1% | SEK 18.00 | SEK 10.00 | n/a | 3 |
| Dec ’24 | SEK 3.54 | SEK 13.67 +286.5% | 24.1% | SEK 18.00 | SEK 10.00 | n/a | 3 |
| Nov ’24 | SEK 3.43 | SEK 14.00 +308.4% | 26.7% | SEK 19.00 | SEK 10.00 | n/a | 3 |
| Oct ’24 | SEK 4.26 | SEK 14.00 +228.6% | 26.7% | SEK 19.00 | SEK 10.00 | n/a | 3 |
| Sep ’24 | SEK 4.12 | SEK 14.00 +240.0% | 26.7% | SEK 19.00 | SEK 10.00 | n/a | 3 |
| Aug ’24 | SEK 5.05 | SEK 17.00 +236.6% | 30.8% | SEK 26.00 | SEK 13.00 | n/a | 4 |
| Jul ’24 | SEK 4.08 | SEK 17.00 +316.7% | 30.8% | SEK 26.00 | SEK 13.00 | n/a | 4 |
| Jun ’24 | SEK 4.68 | SEK 17.00 +262.9% | 30.8% | SEK 26.00 | SEK 13.00 | SEK 4.80 | 4 |
| May ’24 | SEK 6.09 | SEK 17.00 +179.1% | 30.8% | SEK 26.00 | SEK 13.00 | SEK 3.34 | 4 |
| Apr ’24 | SEK 6.78 | SEK 17.67 +160.8% | 33.4% | SEK 26.00 | SEK 13.00 | SEK 3.49 | 3 |
| Mar ’24 | SEK 7.82 | SEK 20.00 +155.8% | 24.5% | SEK 26.00 | SEK 14.00 | SEK 2.72 | 3 |
| Feb ’24 | SEK 6.08 | SEK 22.00 +261.8% | 9.1% | SEK 24.00 | SEK 20.00 | SEK 3.47 | 2 |
| Jan ’24 | SEK 3.08 | SEK 22.00 +614.3% | 9.1% | SEK 24.00 | SEK 20.00 | SEK 3.74 | 2 |
| Dec ’23 | SEK 3.44 | SEK 22.00 +539.5% | 9.1% | SEK 24.00 | SEK 20.00 | SEK 3.54 | 2 |
| Oct ’23 | SEK 3.98 | SEK 28.00 +603.5% | 28.6% | SEK 36.00 | SEK 20.00 | SEK 4.26 | 2 |
| Sep ’23 | SEK 4.15 | SEK 38.00 +815.2% | 5.3% | SEK 40.00 | SEK 36.00 | SEK 4.12 | 2 |
| Aug ’23 | SEK 5.46 | SEK 38.00 +596.6% | 5.3% | SEK 40.00 | SEK 36.00 | SEK 5.05 | 2 |
| Jul ’23 | SEK 7.50 | SEK 38.00 +406.7% | 5.3% | SEK 40.00 | SEK 36.00 | SEK 4.08 | 2 |
| Jun ’23 | SEK 16.74 | SEK 38.00 +127.0% | 5.3% | SEK 40.00 | SEK 36.00 | SEK 4.68 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.